1. No category

The Official Newsletter of the Florida Hemophilia Association
Highlights of the 32nd Annual
SUMMER 2015
INSIDE
Executively Speaking
Page 2
NHF News
Family Education
S Y M P O S I U M
Page 11, 12
Community Corner
Page 6, 9, 10
FHA Resource Center
Page 15
“SAVE THE DATE”
Hispanic Heritage
Miami
September 26
Hispanic Heritage
Orlando
October 10
Guys Day Out
Lago Mar
Country Club
November 8
Swing for the Kids
Lago Mar Country Club
November 16
Holiday Duo
Markham Park
December 13
W
e are proud to announce that this year’s 32nd Annual Family Education Symposium
was a complete success! Our community is very blessed to have such gifted speakers
whom have educated us on how to be the best advocates of our disorder. Doctors, Social
Workers, and others were happy to share their knowledge on bleeding disorders and how to
maintain a healthy as well as a positive lifestyle with one.
Spotlights from this year’s symposium sessions included, “8 techniques for getting
Un-stuck” presented by Patrick Torrey, and “Know It All” by Dr. Joanna Davis and Dr. Robert
F. Sidonio. We are fortunate to have such devoted community members, Lilliam Bervis and
Bobby Monahan, who did an exceptional job as panelists in James Patrick Lynch’s session
“Powering Through”.
As usual, we had tracks for kids, teens, and young adults. The kids enjoyed some fun
activities such as fishing, bowling, and swimming. They were also able to participate in their
very own educational sessions that included interactive programs facilitated by Mike
Rosenthal, followed by the “Get up and Move” that provided kids with a range of activities
(Continue page 2)
ExecutivelySpeaking
MensajeEjecutivo
It’s been an amazing past few months here at FHA so
I thought that I’d take this opportunity to reflect on
some of the programs and activities that have taken
place. Starting the summer off with a “Parents
Empowering Parents” PEP program in Spanish,
followed by the Annual Family Education Symposium,
with over 350 people from all over the state who
enjoyed a wonderful weekend filled with educational
tracks, networking, catching up with old friends and
a whole lot of fun! Shortly after, we headed to Key
Largo with a group of our teens and young adults for
the “Teen and Young Adult Retreat, a “new leadership” program for ages 14
– 20 years of age. The group participated in a myriad of
activities from “Leadership building skills" to snorkeling
alongside dolphins!
Ha sido un asombroso últimos meses aquí en FHA pensé que aprovecharía
esta oportunidad para reflexionar sobre algunos de los programas y
actividades que han tomado lugar. Comenzando el verano con un programa
de "Padres empoderar Padres" PEP en español, seguido por el Simposio
Anual de Educación Familiar, con más de 350 personas de todo el estado, que
disfrutaron de un maravilloso fin de semana lleno de reuniones educativas,
redes, ponerse al día con viejas amistades y un montón de diversión! Poco
después, nos dirigimos a Key Largo con un grupo de nuestros adolescentes
y jóvenes adulto para un programa nuevo de "Adolescentes y Jóvenes adulto
retiro” un nuevo programa de liderazgo para las edades 14 a 20 años de
edad. El grupo participó en un sinnúmero de actividades de "Construcción de
liderazgo" hasta para snorkel junto a delfines!
Then it was off to the NHF Annual Meeting in Dallas! We had
several families representing Florida, thanks to NHF for
providing them with scholarships to attend! The meeting
provided informative and educational sessions that included
tracks for chapters, consumers/new families, medical
providers and for Spanish Speakers. One of the biggest
Robyn
highlights for us was having two of our very own community
members receive prestigious awards! Jeanette Cesta was
the recipient of the “NHF Volunteer of the year” award. Jeanette is what
we call a devoted volunteer because of her willingness to help others! Not
only does she volunteer at FHA by participating on numerous committees
but she also volunteers her time at her church and many of the other
chapters across the country. FHA Walk Chair Robyn Salk received the
“Chapter Recognition Volunteer of the Year” award. Robyn has been a great
asset to FHA and very instrumental in making our “Annual Walk in the
Jungle” a huge success by raising extraordinary funds and much needed
awareness for the bleeding disorder community! Congratulation to Robyn
and Jeanette!
We are looking forward to being one of the host chapters for next year’s NHF
68th Annual meeting and super excited that it will take place in Orlando and
directly preceding will be the WFH World meeting!
Luego, nos fuimos a la reunión anual de la NHF en Dallas! Tuvimos varias
familias que representaron a la Florida, me gustaría dar las gracias a NHF
para proporcionarles becas para asistir! Las reunión dio una sesione
informativo y educativo, hasta unas sesione que incluía pistas de capítulos,
los consumidores/nuevas familias, proveedores de servicios médicos y para
los hablantes español. Uno de los puntos más grandes para
nosotros fue dos de nuestros miembros de nuestra propia
comunidad recibieron premios prestigiosos! Jeanette Cesta
fue la receptora del premio "NHF voluntario del año". Jeanette
es la que llamamos una voluntaria dedicado a su deseo de
ayudar a los demás! No solo es una voluntarios en la FHA,
participa en numerosas grupos pero ella también es voluntaria
de su iglesia y muchas de los otras capítulos en todo el país.
Silla de la caminata de FHA, Robyn Salk recibió el premio
"Capítulo reconocimiento voluntario del año". Robyn ha sido un
Jeanette
provecho para FHA y una herramienta esencial en
asegurándose que nuestra “Caminata Annual” es un éxito enorme levantando
fondos extraordinarios y conocimiento a la comunidad! Felicidades Robyn y
Jeanette!
Estamos mirando adelante a ser uno de los capítulos de patrón para la
reunión anual de la reunión NHF 68th del próximo año y extremadamente
emocionada que se va hacer en Orlando y que precede la reunión mundial
de Hemofilia la WFH!
Be sure to read the newsletter in it’s entirety to find out more about chapter
events and highlights.
Asegúrese de leer el boletín en su totalidad para obtener más información
sobre eventos del capítulo y las reseñas.
See you soon!
¡Hasta pronto!
Debbi Adamkin
FHA Executive Director
Debbi Adamkin
Directora Ejecutiva de FHA
Highlights of the 32nd Annual Family Education Symposium, continued...
that are safe for them to engage in. The teens participated in their separate
sessions that gave them a better understanding of not just themselves, but those
around them in the workshop “The Teenage Brain” presented by Patrick Torrey.
To end a great weekend the kids and teens spent the rest of their Saturday
afternoon bowling and watching a movie.
This year’s symposium was a great success and we cannot wait to see you all
next year. We know that with each coming year our community will continue to
grow and flourish in the care of our bleeding disorders.
(Continue page 3)
2
SUMMER 2015 • LIFELINE
Highlights of the
32nd Annual Family Education Symposium,
continued...
Thank You for Supporting the 32nd Annual
Family Education Symposium!
Symposium Partners
Diamond
Biogen
Gold
Baxalta
Bronze
Bayer Healthcare Pharmaceuticals
Pfizer
Sponsors:
CSL Behring
Emergent Biosolutions
Grifols
Novo Nordisk
Octapharma
Exhibitors:
Accredo Specialty Pharmacy
BioRx
CVS Caremark Specialty Pharmacy
Kedrion Biopharma
Option Care
Other Sponsors:
Palm Beach Visitors & Convention Bureau
Program Speakers and Facilitators:
Lilliam Bervis
Jeanette Cesta
Joanna A. Davis, MD
Patricia Espinosa
Angela Forsyth, PT, DPT
Michael Gil
J Martin Johnston, MD, FAAP
Jeffrey Kallberg, PT
Ed Kuebler, LCSW
Patrick James Lynch
Bobby Monahan
Kate Nammacher, MPH
Miriam Pimentel
Michael Rosenthal
Robert F. Sidonio, Jr, MD, MSc
Ana Spielberg, RN
Patrick Torrey
Christopher E. Walsh,
MD, PHD
Ray White
Sara Workman
Alfred Zweig, RN
Symposium Committee
Chelsey Adamkin
Debbi Adamkin
Jeanette Cesta
Julie Cesta
Bobby Monahan
Ed Moore
Valerie Mooney
Volunteers:
Chelsey Adamkin
Barb Amos
Francisco Bervis
Elise Boston
Dan Capelo
Sara Casey
Julie Cesta
Marge Cesta
Jan Espinosa
Donna Frisella
Dr. Romeena Martinez
Barbara Matias
Ed Moore
Kim Moore
Valerie Mooney
Alida Rivera
Luis Romani
Jon Salk
Robyn Salk
Steve Tejiram
Charlette Thibault
(Continue page 4)
SUMMER 2015 • LIFELINE
3
Highlights of the 32nd Annual Family Education Symposium,
continued...
4
SUMMER 2015 • LIFELINE
Program Facilitator : Perry Parker
Lago Mar Country Club
500 N.W. 12th Avenue, Plantation, FL 33325
Sunday, November 8, 2015 / 2:45pm – 5:30pm
MINI-GOLF CLINIC, DINNER AND RAP SESSION
Please wear appropriate golf attire: Collared Shirt, Shorts, and Sneakers.
No Jeans, Cutoffs or Tank Tops
RSVP by Monday, November 2nd
Email: [email protected]
Phone: 305.235.0717
This program is made possible by
Join us
for an afternoon of family
fun, music, dancing and
delicious food to kick off
the holiday season!
Sunday,
December 13, 2015
11:30am – 3:00pm
We’re having a BAKE-OFF!
Bring your families’ favorite
holiday dessert for a chance to
win a special prize!
Don’t miss out!
RSVP by December 4th to
[email protected]
or (305)
235-0717
CSL Behring
Ladies Luncheon
O
n August 23rd at Billy’s Stone Crab Restaurant a total of thirty-five women arrived early in the morning
ready to take some notes on stress management, where our speaker Jeanette Cesta did a phenomenal job in
her presentation titled “What me worry? Managing stress with a Bleeding Disorder”. She provided the women of
our community with encouragement and reassurance on their daily struggles that sometimes takes a toll on not only
their body’s, but mental health as well. Jeanette hit some very important points such as being a Perfectionist, All or
nothing thinking, and Universalizing. She promoted positive affirmation, to speak to oneself in a kindly manner and
to repeat encouraging phrases like “breath in peace, breathe out love”.
6
SUMMER 2015 • LIFELINE
Submitted byIvan Romero
"During the retreat I
learned various things,
not only about the
bleeding disorder
community but about myself as well. No matter
what your situation or condition may be, there are
no limitations. The world was created to be
explored, and the human body was created to care
for it and discover its beauty. Learning from the
counselors about their experiences and
involvement in the bleeding disorder community
and how they've discovered the beauty of the
world, helped many of us at the retreat open our
eyes. Us as humans, we have our own world inside
and out. We're each unique in our ways. The same
we have to take care of the world, we have to take
care of our own bodies. Our bleeding disorders
make us even more unique from everyone else,
therefore we need more care. It's never
necessarily a bad thing, it makes us different,
beautiful, unique, amazing... it makes us... us.
P.S. Thank you
Debbi and everyone
who made this
amazing weekend
possible!"
SUMMER 2015 • LIFELINE
9
Kiara age 12
visit to Island
I'm writing in regards to our
thank the Florida
Dolphin Care (IDC). I want to
and IDC because
Hemophilia Association (FHA)
going and
every year I look forward to
mal the dolphins
ani
e
orit
fav
my
swimming with
people like me with
and of course meeting other
nice to know I'm
bleeding disorders. It’s always
other kids like me.
not alone and that there are
that the people at
really appreciate everything
r; like the arts and
Island dolphin care center offe
Q lunch. They are
crafts, touch tank and the BB
thank you and I
so nice I just wanted to say
r. My sister
can't wait to go back next yea
a letter but she
Sabrina is too young to write
she also had so
wanted to say thank you and
year and she can't
much fun. This was her first
wait for next year.
Jacob, age 10
"I liked that the dolphins ate
water jello. I liked seeing the
different fish within the bui
lding. I
liked surfing on the board
while
the dolphins were pushing
me. It
was really cool!"
10
SUMMER 2015 • LIFELINE
Emma, age 12
"Dolphin camp was really
fun. I enjoyed working with
other animals. It was
something very amazing!"
NHF • eNews 2015
New MASAC Documents Available
August 5, 2015
I
ssued the following new documents, which were adopted by NHF’s
Board of Directors in June 2015:
MASAC Document #232 was created in direct response to an NHFhosted von Willebrand disease (VWD) Summit. The purpose of the
summit was to identify, through vigorous discussion, gaps in care for
individuals with VWD. MASAC produced a document that both
summarizes the discussion highlights and provides subsequent
recommendations that seek to address the healthcare needs of an
underserved US VWD population.
MASAC Document #233 covers the safe and effective at-home use of
bypassing agents in patients with hemophilia A or B and inhibitors. The
recommendations within the document stress the importance of
education and information relevant to factor administration, symptom
identification and emergency response.
MASAC Document #234 encompasses recommendations relevant to
the testing, assessment and treatment of hepatitis C viral (HCV)
infection in people with bleeding disorders. The document also includes
a recommendation concerning reimbursement for, and access to, newer
and more effective HCV drugs.
MASAC Document #235 includes the council’s most recent series of
treatment recommendations, including information on currently
available therapies.
To request a hard copy of any current documents, please contact
HANDI, NHF’s information resource center: [email protected]
or 1(800)424-2634.
Nuevos documentos del MASAC están ahora disponibles
Agosto 5, 2015
E
l Consejo Asesor Médico y Científico (MASAC) de la National
Hemophilia Foundation (NHF) emitió los siguientes nuevos
documentos, los cuales la Junta de Directores de la NHF adoptó en
junio de 2015:
El documento n.º 232 del MASAC se creó como respuesta directa a la
Cumbre sobre la enfermedad de von Willebrand (VWD) patrocinada
por la NHF. El objetivo de dicha cumbre fue identificar, a través de un
enérgico debate, las deficiencias en la atención de las personas con
VWD. El MASAC elaboró un documento que resume los puntos
esenciales del debate y brinda recomendaciones posteriores que buscan
abordar las necesidades sanitarias de una población de pacientes con
VWD en los EE. UU. no atendida debidamente.
El documento n.º 233 del MASAC cubre el uso seguro y eficaz en el
hogar de los fármacos que eluden a los inhibidores en pacientes que
padecen de hemofilia A o B y presentan inhibidores. Las
recomendaciones en este documento enfatizan la importancia de la
concientización y la información en lo que se refiere a la administración
del factor, la identificación de los síntomas y la respuesta en casos de
emergencia.
El documento n.º 234 del MASAC incluye recomendaciones
relacionadas con los análisis, la evaluación y el tratamiento de la
infección por el virus de la hepatitis C (VHC) en personas con
trastornos hemorrágicos. El documento también incluye una
recomendación sobre el rembolso por los fármacos contra el VHC y el
acceso a fármacos nuevos y más eficaces.
El documento n.º 235 del MASAC incluye la serie de recomendaciones
sobre tratamiento más reciente del consejo, entre ella información
sobre los tratamientos actualmente disponibles.
Para solicitar una copia impresa de cualquier documento vigente,
comuníquese con HANDI, el centro de recursos informativos de la
NHF: [email protected] o al 1(800)424-2634.
SUMMER 2015 • LIFELINE
11
NHF • eNews 2015
FDA Approves New Therapies
for HCV, Genotype 3 and 4
August 5, 2015
O
n July 24, 2015, the US Food and Drug Administration (FDA)
approved two new orally administered drugs for use in patients
with hepatitis C virus (HCV) infections. Bristol-Myers Squibb’s Daklinza™
(daclatasvir) is now approved for use in patients with genotype 3, in
combination with sofosbuvir (Sovaldi®, Gilead). AbbVie Inc.’s Technivie™
was approved for use in patients with genotype 4, without scarring and
poor liver function (cirrhosis), in combination with ribavirin.
The Daklinza™ approval was based in part on a safety and efficacy trial
in which the drug was administered in combination with sofosbuvir to
152 treatment-naive and treatment-experienced participants with
chronic HCV genotype 3 infection. Trial participants received
Daklinza™ 60 milligrams (mg) with sofosbuvir 400 mg once daily for 12
weeks. They were then monitored for 24 weeks post treatment. Results
showed that 98% of the treatment-naive participants with no cirrhosis of
the liver and 58% of the treatment-naive participants with cirrhosis
achieved sustained virologic response (SVR), meaning they no longer
had detectable virus in their blood. Of the participants who were
treatment-experienced, 92% with no cirrhosis of the liver and 69% with
cirrhosis achieved SVR.
“Today’s approval provides a new option for patients with genotype 3
HCV, including those patients who cannot tolerate ribavirin,” said
Edward Cox, MD, director of the Office of Antimicrobial Products in
the FDA’s Center for Drug Evaluation and Research.
Technivie™, a combination of the drugs ombitasvir, paritaprevir and
ritonavir, was approved based on the findings of a safety/efficacy study
that included 135 people with chronic HCV genotype 4 infections.
These patients were not affected by cirrhosis. 91 of the trial
participants received Technivie with ribavirin once-a-day for 12 weeks;
44 participants received Technivie™ once daily without ribavirin for
12 weeks. Results showed that 100% of the participants who received
Technivie™ with ribavirin achieved SVR. Those who received
Technivie™ without ribavirin, achieved an SVR of 91%.
“Today’s approval provides the first treatment option for patients with
genotype 4 HCV infections without requiring use of interferon,” said
Cox.
Source: FDA news releases, July 24, 2015
La FDA aprueba nuevos tratamientos
contra el VHC, genotipos 3 y 4
5 de agosto de 2015
E
l 24 de julio de 2015, la Administración de Alimentos y Medicamentos de los EE. UU. (FDA) aprobó dos fármacos nuevos de
administración oral para el uso en pacientes infectados por el virus de la
hepatitis C (VHC). Daklinza™ (daclatasvir), de Bristol-Myers Squibb, está
ahora aprobado para su uso en pacientes con el genotipo 3, en combinación
con sofosbuvir (Sovaldi®, Gilead). Technivie™, de AbbVie Inc., se aprobó
para el uso en pacientes con el genotipo 4, sin fibrosis ni funcionamiento
hepático deficiente (cirrosis), en combinación con ribavirina.
La aprobación de Daklinza™ se basó en parte en un ensayo sobre
seguridad y eficacia en el cual el fármaco se administró en combinación
con sofosbuvir a 152 participantes (algunos sin tratamiento previo y otros
con tratamiento previo) con infección crónica por el genotipo 3 del VHC.
Los participantes en el ensayo recibieron 60 miligramos (mg) de
Daklinza™ y 400 mg de sofosbuvir una vez al día durante 12 semanas.
Luego se les dio seguimiento durante 24 semanas después del tratamiento.
Los resultados mostraron que el 98% de los participantes que no habían
recibido tratamiento previo y que no tenían cirrosis y el 58% de los
participantes que no habían recibido tratamiento previo y que tenían
cirrosis alcanzaron una respuesta virológica sostenida (RVS), es decir, ya no
tenían el virus detectable en la sangre. De los participantes que habían
recibido tratamiento previo, el 92% de los que no tenían cirrosis hepática y
el 69% de los que tenían cirrosis alcanzaron la RVS.
12
SUMMER 2015 • LIFELINE
“La aprobación concedida hoy brinda una nueva opción para los
pacientes con el genotipo 3 del VHC, incluidos aquellos pacientes que no
pueden tolerar la ribavirina”, expresó el Dr. Edward Cox, director del
Departamento de Productos Antimicrobianos del Centro para la
Evaluación e Investigación de Fármacos de la FDA.
Technivie™, una combinación de los fármacos ombitasvir, paritaprevir y
ritonavir, se aprobó con base en los resultados de un estudio de seguridad
y eficacia que incluyó 135 personas con infección por el genotipo 4 del
VHC. Estos pacientes no padecían de cirrosis. De los participantes en el
ensayo, 91 recibieron Technivie™ con ribavirina una vez al día durante
12 semanas; 44 participantes recibieron Technivie™ una vez al día, sin
ribavirina, durante 12 semanas. Los resultados mostraron que el 100% de
los participantes que recibieron Technivie™ con ribavirina alcanzaron la
RVS. De aquellos que recibieron Technivie™ sin ribavirina, el 91%
alcanzaron una RVS.
“La aprobación concedida hoy proporciona la primera opción de
tratamiento para los pacientes infectados por el genotipo 4 del VHC sin
que sea necesario usar interferón”, dijo Cox.
Fuente: Comunicado de prensa de la FDA, 24 de julio de 2015
FHA ResourceCenter
MISSION STATEMENT
CONTACT NUMBERS
The Florida Hemophilia Association, Inc (FHA) is a Not-for-Profit organization that is
dedicated to enhancing the quality of life in the bleeding disorders community by creating
programs and services that provide education, emotional support and advocacy. We are
contributing toward research to ultimately find a cure.
HEMOPHILIA CLINICS
All Children’s Outpatient
Care Clinic
Pediatric Cancer and
Blood Disorders Center
601 5th Street South,
Third Floor
St. Petersburg, FL 33701
Phone: (727) 767-4931
www.allkids.org
Center for Children’s
Cancer and Blood
Disorders at Arnold
Palmer Hospital
for Children
92 West Miller St., MP 318
Orlando, FL 32806
Phone: (321) 841-8588
www.orlandohealth.com
Joe DiMaggio
Children’s Hospital
Pediatric Specialty Center
1150 N. 35th Ave.
Suite 520
Hollywood, FL 33021
Phone: (954) 986-2234
Lee Memorial Hospital
Department of Pediatric
Hematology & Oncology
9981 So. Healthpark Dr.
Suite 156
Ft. Myers, FL 33908
Phone: (239) 332-1111
Nemours Children’s
Clinic, Jacksonville
Department of Pediatric
Hematology/Oncology
807 Children’s Way
Jacksonville, FL 32207
Phone: (904) 697-3789
(904) 697-3600
www.nemours.com
University of Florida
Department of Medicine
Adult Hemophilia
P.O. Box 100277
Gainesville, FL 32610
Phone: (352) 265-0725
University of Florida
Pediatric Hematology/
Oncology
P.O. Box 100296
Gainesville, FL 32610
Phone: (352) 273-9120
www.peds.ufl.edu/
divisions/hemonc/
Nemours Children’s
Clinic, Orlando
Department of Pediatric
Hematology/Oncology
13535 Nemours Parkway
Orlando, FL 32827
Phone: (904) 697-3789,
(904) 697-3600
Sacred Heart Pediatric
Hemophilia Program,
Pensacola
Phone: (850) 416-7712
St. Joseph’s Children’s
Hospital
Pediatric Hematology
Oncology Out-patient
Clinic
3001 W. Dr. Martin
Luther King Jr. Blvd.
Tampa, FL 33607
Phone: (813) 554-8294
or (813) 321-6820
The University of Miami
Hemophilia Treatment
Center
Pediatric Clinic Location
Alex’s Place at Sylvester
1475 NW 12th Avenue
Suite C103
Miami, FL 33136
Phone: (305) 689-7210
Adult Clinic Location
ACCW-3A
1611 NW 12th Avenue
Miami, FL 33136
Phone: (305) 243-6925
www.htcextras.org
USF Adult Hemophilia
Center
Department of Internal
Medicine
12901 Bruce B. Downs
Boulevard, MDC 19
Tampa, FL 33612
Phone: (813) 974-1325
Do the 5
1 Get an annual comprehensive check-up at a hemophilia treatment
center. 2 Get vaccinated – Hepatitis A and B are preventable.
3 Treat bleeds early and adequately. 4 Exercise to protect your
joints. 5 Get tested regularly for blood-borne infections
Florida Hemophilia
Association Office
(888) 880-8330
President
Jon Salk
Executive Director
Debbi Adamkin
(305) 235-0717
[email protected]
National Hemophilia
Foundation
(800) 424-2634
Hemophilia Federation of America
(800) 230-9797
LA Kelley
Communications, Inc.
Free resource material on
Hemophilia
(978) 352-7657
ABOUT THIS PUBLICATION
LIFE LINE is the official
Newsletter of the Florida
Hemophilia Association.
It is produced quarterly and
distributed free of charge to
requesting members of the
bleeding disorder community.
Florida Hemophilia
Association Headquarters
915 Middle River Drive, Suite 421
Ft. Lauderdale, FL 33304
Toll Free: (888) 880-8330
www.floridahemophilia.org
Newsletter Committee:
Debbi Adamkin, Maria Rubin
Translation:
Roxana Ambrosini, Lilliam Bervis,
Roxanna Delgado
Design and Production:
Group M, Advertising & Design
305-235-2538
SUMMER 2015 • LIFELINE
15
Florida Hemophilia Association
(Formerly known as Florida Chapter, NHF)
915 Middle River Drive, Suite 421
Ft. Lauderdale, FL 33304
FORMAT:
4 Person Scramble
Shotgun Start: 12:15 p.m.
Awards Dinner 5:00 p.m.
FOURSOME:
$800
Includes: Golf, Range
Balls, Golf Shirt, Lunch
and Dinner
SPONSORSHIP
Opportunities are
Available!
For more information, call:
305-235-0717
E-mail: [email protected]
www.floridahemophilia.org
TITLE SPONSOR
Baxalta
MAJOR SPONSORS
Bayer, CSL Behring, Pfizer